Regulatory Affairs and Clinical Operations Vice Presidents Add Key Expertise as Company Prepares to Initiate U.S. Clinical Trials

SEATTLE, BOSTON & TOKYO--(BUSINESS WIRE)--Aurion Biotech, whose mission is to restore vision to millions of patients with its life-changing regenerative therapies, today announced it has appointed Sherita Hall as vice president, clinical operations and Sterling Chung as vice president, global regulatory affairs.

�I�m delighted to welcome Sherita and Sterling to Aurion Biotech,� said Greg Kunst, Aurion Biotech chief executive officer. �Their strategic and operational expertise in Regulatory Affairs and Clinical Operations will be essential to our success, as we prepare to initiate clinical trials here in the U.S. The combination of our company�s innovative technology, novel first drug candidate, engaged investors, and the high caliber of our board of directors and medical advisors means that we continue to attract top leadership to our team.�

�I am grateful for the opportunity to leverage my experience in clinical trial strategy and execution, to bring our transformational cell therapy to patients in need,� said Ms. Hall. �I look forward to supporting the company�s next phase of growth.�

Ms. Hall is responsible for leading the execution of the company�s clinical strategy alongside the clinical and medical teams. Prior to joining Aurion Biotech, she led clinical operations and program management at Ocular Therapeutix. At Regenxbio, Ms. Hall led the team assigned to wet age-related macular degeneration (AMD). She also has held clinical operations and quality roles at Radius Health, Spinal Motion, Baxter Healthcare, and Otsuka. Ms. Hall holds a BA in Psychology from American University and a MA in Human Services Counseling from Liberty University.

�I�ve followed Aurion�s trajectory for some time, and now I�m excited to help propel the company�s future successes as a team member,� said Mr. Chung. �We have a winning formula: talented and mission-driven people, a very promising drug candidate, and a clear path forward.�

Mr. Chung has more than 19 years of pharmaceutical regulatory affairs experience. He has successfully worked on multiple NDA and BLA submissions and approvals in the United States, Canada, the European Union and Japan. Before joining Aurion Biotech, Mr. Chung held regulatory leadership roles at Neoleukin Therapeutics, Molecular Templates, Immatics US, Seattle Genetics, Gilead Sciences, Astellas Pharmaceuticals, Takeda Pharmaceuticals, and Abbott Laboratories. Mr. Chung holds a BA in Political Science and a BS in Biology from the University of Michigan, and a regulatory and quality assurance certificate from Purdue University.

About Aurion Biotech

With offices in Seattle, Boston and Tokyo, Aurion Biotech is a clinical-stage biotech company, whose mission is to restore vision to millions of patients with its life-changing regenerative therapies. The Company�s first candidate is for the treatment of corneal edema secondary to endothelial dysfunction, and is one of the first clinically validated cell therapies for corneal care. Aurion Biotech is the recipient of the prestigious Prix Galien award for best start-up in biotech. The Company is preparing for clinical trials in the U.S. Privately held, Aurion Biotech is backed by leading investors that include Deerfield, Alcon, Petrichor, Flying L Partners, Falcon Vision / KKR, and Visionary Ventures. To learn more about Aurion Biotech, visit www.aurionbiotech.com.

Contacts

Judith McGarry

415-971-2900

[email protected]

Michele Gray

917-449-9250

[email protected]